AVA6000 pro® IVD product doxorubicin: Conducting Phase 1a dose escalation study (in UK and with IND approved for US sites) with expected read out in late Q3.
9 weeks
Wonder when new (or old) investors will start to take positions for that data read. The hardcore LTH here very confident with the evidence we have seen to date. SP very steady now but there surely has to be a time when it starts to rise pre data result.